

**Myelosuppression: The Challenge of Managing Invasive Fungal Infections in Patients With Acute Myelogenous Leukemia**

SCEPTER™ values your opinions in helping us further our commitment to excellence in our educational programs. **NOTE:** a CME certificate is issued only upon receipt of your completed evaluation form. We will be sending you an additional questionnaire in approximately 2 months to help determine the enduring value and improve our programs.

**PLEASE ANSWER THE FOLLOWING QUESTIONS BY CIRCLING OR CHECKING THE APPROPRIATE RATING:**

	<b>Very Dissatisfied</b>	<b>Dissatisfied</b>	<b>Neutral</b>	<b>Satisfied</b>	<b>Very Satisfied</b>
1) Overall, how satisfied are you with this program?	1	2	3	4	5
2) Please indicate how you feel about the following statements concerning this program:	<b>Strongly Disagree</b>	<b>Disagree</b>	<b>Neutral</b>	<b>Agree</b>	<b>Strongly Agree</b>
a. The program met the stated educational objectives.	1	2	3	4	5
Upon completion of the program, participants will be able to:					
• Discuss trends in the epidemiology of IFIs and methods for identifying the infections in patients with AML	1	2	3	4	5
• Describe morbidity expected to occur with the use of cytotoxic chemotherapeutic regimens in the management of AML	1	2	3	4	5
• Explain treatment strategies and prophylactic options for the management of IFIs in patients with cancer	1	2	3	4	5
• Explain strategies to promote hematopoiesis and improve immune response in patients with cancer	1	2	3	4	5
b. The information presented in this activity was pertinent to my professional needs	1	2	3	4	5
c. The program was well organized	1	2	3	4	5

3) I would recommend this program to a colleague.       Yes       No  
 Why / Why not recommend this program?

---



---

4) This program was free of commercial bias.       Yes       No  
 If no, please describe the bias:

---



---

5) Please rate the faculty using the following scale: 1 = Poor 2 = Fair 3 = Average 4 = Good 5 = Excellent

Faculty	Knowledge of Subject Matter					Effectiveness of Delivery				
Amar Safdar, MD, MBBS, FACP, FIDSA	1	2	3	4	5	1	2	3	4	5
Edmund K. Waller, MD, PhD, FACP	1	2	3	4	5	1	2	3	4	5

**COMMENTS**

1) Is there any ONE thing that you learned at this program which you can apply, in the next six months that will affect your patient's healthcare outcomes?  
 Yes       No       Not Applicable

Please explain:

---



---

2) How would you improve this program?

---



---

3) What topics, speakers, etc. would you like to see in future programs?

---



---

## OUTCOMES QUESTIONS

1. Non-*Aspergillus* species are becoming an increasing threat in the setting of AML.
  - a. Strongly disagree
  - b. Disagree
  - c. Neutral
  - d. Agree
  - e. Strongly agree
2. Occurrences of infections are associated with the intensity of chemotherapy in children with AML.
  - a. Strongly disagree
  - b. Disagree
  - c. Neutral
  - d. Agree
  - e. Strongly agree
3. In your opinion, which of the following can be a drawback associated with the use of antifungal prophylaxis in the setting of AML?
  - a. Compromises diagnostic efficacy of fungal antigen assays
  - b. Breakthrough infections due to drug-nonsusceptible molds or yeasts
  - c. Emergence of drug-resistant strains of organisms
  - d. All of the above
4. In older adults with de novo AML, the use of GM-CSF has been associated with a shorter median time to neutrophil recovery.
  - a. Strongly disagree
  - b. Disagree
  - c. Neutral
  - d. Agree
  - e. Strongly agree
5. In treating invasive fungal infections in patients with AML, how confident are you that the infection is caused by *Aspergillus* species?
  - a. Extremely confident
  - b. Confident
  - c. Somewhat confident
  - d. Not confident at all
6. TL is a 57-year-old, 5' 8", 170 pound male with newly diagnosed AML, who is admitted to the hospital for induction chemotherapy with cytarabine and daunorubicin. Five days after his chemotherapy, his absolute neutrophil count was 210 cells/mm<sup>3</sup>. He was afebrile, serum creatinine was 0.9 mg/dL, blood pressure and heart rate were 128/82 and 72. His central catheter exit site functioned normally and there were no inflammatory changes evident at the exit site. Which of the following are appropriate interventions?
  - a. Begin levofloxacin 500 mg per day orally
  - b. Begin fluconazole 200 mg per day orally
  - c. Continue to routinely monitor vitals with no intervention currently
  - d. A and B
7. Twenty-four hours later, TL's neutrophil count was 100 cells/mm<sup>3</sup>, temperature was 39.3°C, blood pressure, heart rate and respiratory rate were all within normal limits. Routine cultures from yesterday showed no bacterial or fungal growth to date. Gram stain showed scattered gram-positive cocci. What would be an appropriate intervention?
  - a. Repeat blood cultures peripherally and centrally
  - b. Begin empiric broad-spectrum antibiotics and antifungals
  - c. Begin GM-CSF 250 mcg/m<sup>2</sup>/day
  - d. A, B, and C
  - e. B and C

**DEMOGRAPHICS**

1) What is your primary profession? (Please choose the one area that best fits you.)

- Physician                                       RN     Nurse Practitioner
- Physician Assistant                               LPN/LVN     Other: \_\_\_\_\_

2) What is your primary specialty? (Please choose the one area that best fits you.)

- Oncology     Primary Care
- Infectious Disease                                       Other: \_\_\_\_\_

3) How did you first learn about this program?

- Brochure     Telephone Reservations Center                                       Advertisement                                       Colleague
- Website / internet                                       Fax     E-Mail     Other: \_\_\_\_\_

4) Please check the top three (3) reasons why you decided to participate in this activity?

- Quality of speakers                                       Apparent value for expense                                       Convenience of format
- Needed credits     Topics     Other: \_\_\_\_\_

**ADDITIONAL INFORMATION**

**Future Programs**

Yes, SCEPTER has my permission to fax and/or e-mail information to me about future CE activities.

To better define and meet the CME needs of health care professionals and enhance future CME activities, SCEPTER will conduct an outcomes measurement survey following the conclusion of the program. This follow-up survey is designed to measure changes to attendees' practice behaviors that are a result of their participation in this CME activity. We greatly appreciate your participation.

**CONTACT INFORMATION**

**NOTE:** we require completion of this information in order to receive credit for participation in this educational activity

Name: \_\_\_\_\_ Degree: MD DO PharmD RPh NP RN PA Other \_\_\_\_\_

Specialty: \_\_\_\_\_ Profession (if other than degree): \_\_\_\_\_

Affiliation: \_\_\_\_\_

Street: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ Zip Code: \_\_\_\_\_

Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ E-mail: \_\_\_\_\_

**Please check one**

- Physician:** To receive a maximum of 1.0 *AMA PRA Category 1 Credit*<sup>TM</sup>
- Nurse:** To receive a maximum of 1.0 CNA/ANCC contact hours
- Other:** To receive a certificate of completion

I certify my actual time spent to complete this educational activity to be \_\_\_\_\_ hour(s). (Maximum of 1.0 hour)

Signature \_\_\_\_\_

**OBTAINING CREDIT**

You may fax or mail the completed form to the address listed below.

**SCEPTER**  
**Attn: Sharine Newby**  
**8 Skyline Drive**  
**Hawthorne, New York 10532**  
**Fax: 1-866-401-4145**

Healthcare professionals will receive a CE certificate via US Mail within 3-4 weeks upon receipt of the completed evaluation form.

*Thank you for your participation.*

